Yan MH, Hou XB, Cai BN, Qu BL, Dai XK, Liu F. Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma. World J Clin Cases 2020; 8(24): 6315-6321 [PMID: 33392312 DOI: 10.12998/wjcc.v8.i24.6315]
Corresponding Author of This Article
Fang Liu, MD, Chief Doctor, Department of Radiotherapy, The First Medical Center of the Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. liufangfsg@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mao-Hui Yan, Bo-Ning Cai, Bao-Lin Qu, Xiang-Kun Dai, Fang Liu, Department of Radiotherapy, The First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China
Xiao-Bin Hou, Department of Thoracic Surgery, The First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Yan MH, Qu BL, and Liu F designed the research study; Yan MH, Hou XB, Dai XK, and Cai BN performed the research; Yan MH and Liu F analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of General Hospital of the Chinese People's Liberation Army Institutional Review Board (Approval No. S2017-001-02).
Conflict-of-interest statement: Mao-Hui Yan has received research funding from the Open Project of National Clinical Research Center for Geriatric Diseases (No: NCRCG-PLAGH-2017004); Fang Liu has received research funding from Clinical Research Support Fund of PLA General Hospital (No: 2016FC-CXYY-2004).
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Liu, MD, Chief Doctor, Department of Radiotherapy, The First Medical Center of the Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. liufangfsg@163.com
Received: September 8, 2020 Peer-review started: September 8, 2020 First decision: September 24, 2020 Revised: October 8, 2020 Accepted: November 2, 2020 Article in press: November 2, 2020 Published online: December 26, 2020
Core Tip
Core Tip: Esophageal cancer is one of the most common malignant tumors of the digestive system worldwide, with an estimated 572000 new cases and 509000 deaths annually. Treatments for locally advanced esophageal cancer include surgery and radical chemoradiotherapy. Although surgery is one of the mainstream treatments for esophageal cancer, the efficacy of surgery alone is poor. In recent years, neoadjuvant chemoradiotherapy combined with surgery has been gradually applied in patients with locally advanced thoracic esophageal cancer, but its effectiveness and safety remain unclear. In this clinical trial, we prospectively investigated the efficacy and safety of neoadjuvant chemoradiotherapy plus surgery in the treatment of thoracic esophageal squamous cell carcinoma.
